BRPI0611202B8 - compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4 - Google Patents
compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4 Download PDFInfo
- Publication number
- BRPI0611202B8 BRPI0611202B8 BRPI0611202A BRPI0611202A BRPI0611202B8 BR PI0611202 B8 BRPI0611202 B8 BR PI0611202B8 BR PI0611202 A BRPI0611202 A BR PI0611202A BR PI0611202 A BRPI0611202 A BR PI0611202A BR PI0611202 B8 BRPI0611202 B8 BR PI0611202B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- receptor agonists
- carboxamide compounds
- benzimidazole carboxamide
- relates
- Prior art date
Links
- XIZCDQOKKYYCRH-UHFFFAOYSA-N 1h-benzimidazole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=NC2=C1 XIZCDQOKKYYCRH-UHFFFAOYSA-N 0.000 title abstract 2
- 108091005482 5-HT4 receptors Proteins 0.000 title abstract 2
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68447805P | 2005-05-25 | 2005-05-25 | |
US68446605P | 2005-05-25 | 2005-05-25 | |
US60/684.478 | 2005-05-25 | ||
US60/684.466 | 2005-05-25 | ||
US74841505P | 2005-12-08 | 2005-12-08 | |
US60/748.415 | 2005-12-08 | ||
PCT/US2006/020085 WO2006127815A2 (en) | 2005-05-25 | 2006-05-24 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0611202A2 BRPI0611202A2 (pt) | 2010-08-24 |
BRPI0611202B1 BRPI0611202B1 (pt) | 2019-09-24 |
BRPI0611202B8 true BRPI0611202B8 (pt) | 2019-09-24 |
BRPI0611202C1 BRPI0611202C1 (pt) | 2021-05-25 |
Family
ID=37452788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0611202A BRPI0611202C1 (pt) | 2005-05-25 | 2006-05-24 | compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4 |
Country Status (27)
Country | Link |
---|---|
US (10) | US7759363B2 (pt) |
EP (1) | EP1899324B1 (pt) |
JP (2) | JP5072111B2 (pt) |
KR (1) | KR101333280B1 (pt) |
AR (1) | AR057327A1 (pt) |
AT (1) | ATE535523T1 (pt) |
AU (1) | AU2006250009B2 (pt) |
BR (1) | BRPI0611202C1 (pt) |
CA (1) | CA2607280C (pt) |
CY (1) | CY1112366T1 (pt) |
DK (1) | DK1899324T3 (pt) |
EA (1) | EA013240B1 (pt) |
ES (1) | ES2376115T3 (pt) |
HK (1) | HK1110980A1 (pt) |
HR (1) | HRP20120108T2 (pt) |
IL (1) | IL186883A (pt) |
MA (1) | MA29541B1 (pt) |
MX (1) | MX2007014762A (pt) |
MY (1) | MY147756A (pt) |
NO (1) | NO339658B1 (pt) |
NZ (1) | NZ563068A (pt) |
PE (1) | PE20061446A1 (pt) |
PL (1) | PL1899324T3 (pt) |
PT (1) | PT1899324E (pt) |
SI (1) | SI1899324T1 (pt) |
TW (1) | TWI388555B (pt) |
WO (1) | WO2006127815A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2184A (en) * | 2003-09-03 | 2010-12-02 | Pfizer | Benzimidazolone compounds having 5-HT4 receptor agonistic activity. |
US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
US7256294B2 (en) * | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
AU2010229142A1 (en) * | 2009-03-23 | 2011-10-13 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
AU2010236734B2 (en) * | 2009-04-13 | 2015-06-11 | Theravance Biopharma R&D Ip, Llc | 5-HT4 receptor agonist compounds for treatment of cognitive disorders |
AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
WO2011092290A1 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists |
WO2011095450A1 (en) | 2010-02-02 | 2011-08-11 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
WO2015020204A1 (ja) * | 2013-08-09 | 2015-02-12 | 参天製薬株式会社 | 3,3-ジメチル-3,4-ジヒドロ-1h-キノキサリン-2-オン誘導体の製造方法およびその製造方法の中間体 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO984B1 (en) * | 1977-10-11 | 1979-12-01 | بيتشام غروب ليمتد | A dry pharmaceutical compound with a suitable dosage unit for oral administration |
ES2109190B1 (es) | 1996-03-22 | 1998-07-01 | Univ Madrid Complutense | Nuevos derivados de bencimidazol con afinidad por los receptores serotoninergicos 5-ht /5-ht |
JPH111472A (ja) | 1996-04-30 | 1999-01-06 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体及びそれを含有する医薬組成物 |
HUP0101511A3 (en) | 1998-04-28 | 2002-12-28 | Dainippon Pharmaceutical Co | 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds |
CA2349227C (en) | 1998-11-03 | 2008-02-05 | Basf Aktiengesellschaft | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
US6353005B1 (en) * | 1999-03-02 | 2002-03-05 | Sepracor, Inc. | Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist |
ES2154605B1 (es) | 1999-09-14 | 2001-11-16 | Univ Madrid Complutense | Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3 |
JP2001122784A (ja) | 1999-10-27 | 2001-05-08 | Dainippon Pharmaceut Co Ltd | 1−[(1−置換−4−ピペリジニル)メチル]−4−ピペリジン誘導体からなる医薬 |
AU7532601A (en) * | 2000-06-07 | 2001-12-17 | Aryx Therapeutics | Materials and methods for the treatment of gastroesophageal reflux disease |
US6696468B2 (en) * | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
ES2285227T3 (es) | 2002-08-05 | 2007-11-16 | Eli Lilly And Company | Arilbenzodiazepinas sustituidas con piperazina. |
CA2499494A1 (en) * | 2002-09-20 | 2004-04-01 | Pfizer Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
JP2004277320A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1,4−ジ置換ピペリジン誘導体およびそれを含有する医薬組成物 |
JP2004277319A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(4−ピペリジニルメチル)ピペリジニルアミド誘導体およびそれを含有する医薬組成物 |
JP2004277318A (ja) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1−(1−置換カルボニル−4−ピペリジニルメチル)ピペリジン誘導体およびそれを含有する医薬組成物 |
AP2184A (en) * | 2003-09-03 | 2010-12-02 | Pfizer | Benzimidazolone compounds having 5-HT4 receptor agonistic activity. |
MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
US7256294B2 (en) | 2005-05-25 | 2007-08-14 | Theravance, Inc. | Crystalline form of a benzimidazole-carboxamide medicinal compound |
-
2006
- 2006-05-17 MY MYPI20062263A patent/MY147756A/en unknown
- 2006-05-22 TW TW095118168A patent/TWI388555B/zh active
- 2006-05-23 PE PE2006000543A patent/PE20061446A1/es active IP Right Grant
- 2006-05-24 AU AU2006250009A patent/AU2006250009B2/en not_active Ceased
- 2006-05-24 KR KR1020077030010A patent/KR101333280B1/ko active IP Right Grant
- 2006-05-24 PL PL06760341T patent/PL1899324T3/pl unknown
- 2006-05-24 EA EA200702612A patent/EA013240B1/ru not_active IP Right Cessation
- 2006-05-24 CA CA2607280A patent/CA2607280C/en active Active
- 2006-05-24 DK DK06760341.5T patent/DK1899324T3/da active
- 2006-05-24 AT AT06760341T patent/ATE535523T1/de active
- 2006-05-24 BR BRPI0611202A patent/BRPI0611202C1/pt not_active IP Right Cessation
- 2006-05-24 US US11/439,671 patent/US7759363B2/en active Active
- 2006-05-24 SI SI200631257T patent/SI1899324T1/sl unknown
- 2006-05-24 WO PCT/US2006/020085 patent/WO2006127815A2/en active Application Filing
- 2006-05-24 MX MX2007014762A patent/MX2007014762A/es active IP Right Grant
- 2006-05-24 PT PT06760341T patent/PT1899324E/pt unknown
- 2006-05-24 AR ARP060102166A patent/AR057327A1/es active IP Right Grant
- 2006-05-24 EP EP06760341A patent/EP1899324B1/en active Active
- 2006-05-24 NZ NZ563068A patent/NZ563068A/en not_active IP Right Cessation
- 2006-05-24 ES ES06760341T patent/ES2376115T3/es active Active
- 2006-05-24 US US11/920,817 patent/US8143279B2/en not_active Expired - Fee Related
- 2006-05-24 JP JP2008513672A patent/JP5072111B2/ja not_active Expired - Fee Related
-
2007
- 2007-10-24 IL IL186883A patent/IL186883A/en active IP Right Grant
- 2007-12-10 MA MA30466A patent/MA29541B1/fr unknown
- 2007-12-17 NO NO20076481A patent/NO339658B1/no not_active IP Right Cessation
-
2008
- 2008-05-19 HK HK08105518.4A patent/HK1110980A1/xx not_active IP Right Cessation
-
2010
- 2010-06-09 US US12/796,902 patent/US8377964B2/en active Active
-
2012
- 2012-02-01 HR HR20120108T patent/HRP20120108T2/hr unknown
- 2012-02-17 CY CY20121100168T patent/CY1112366T1/el unknown
- 2012-07-23 JP JP2012162692A patent/JP2012197322A/ja not_active Withdrawn
-
2013
- 2013-01-16 US US13/742,783 patent/US20130273568A1/en not_active Abandoned
-
2014
- 2014-09-17 US US14/488,520 patent/US9428489B2/en active Active
-
2016
- 2016-07-28 US US15/221,841 patent/US9975877B2/en active Active
-
2018
- 2018-04-19 US US15/956,958 patent/US10233172B2/en active Active
-
2019
- 2019-01-29 US US16/260,984 patent/US10696656B2/en not_active Expired - Fee Related
-
2020
- 2020-05-22 US US16/881,209 patent/US11254655B2/en active Active
-
2022
- 2022-01-12 US US17/573,814 patent/US20220274957A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0611202B8 (pt) | compostos de benzimidazola-carboxamida como agonistas do receptor 5-ht4 | |
BRPI0507791A (pt) | compostos de indazol-carboxamida como agonistas do receptor 5-ht4 | |
MY155036A (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
NO20073182L (no) | Indazol-karboksamidforbindelser | |
NO20063620L (no) | Arylanilinderivater som beta2 adrenergiske receptoragonister | |
DE602006019595D1 (de) | Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors | |
ATE441646T1 (de) | 5-ht4-rezeptoragonistenverbindungen | |
ATE431824T1 (de) | Chinolinon-carboxamid-verbindungen | |
BRPI0511695A (pt) | agonistas de receptor (beta)2 adrenérgico diamina | |
BRPI0607015A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto | |
BRPI0407508B8 (pt) | compostos derivados de bifenila, composição farmacêutica e uso dos mesmos | |
NO20076498L (no) | Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren | |
DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
BRPI0608392A2 (pt) | compostos de quinolinona como agonistas do receptor 5-ht4 | |
BRPI0606639A2 (pt) | novo processo para a preparação de indóis substituìdos | |
ATE450511T1 (de) | Kristalline formen eines arylanilin-beta-2- adrenergenrezeptor-agonists | |
DK1861360T3 (da) | Pyrrolidin-derivater som histamin-H3-receptorantagonister | |
BRPI0821611A8 (pt) | Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu | |
MY143574A (en) | Carbamate compounds as 5-ht4 receptor agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: THERAVANCE BIOPHARMA RANDD IP, LLC (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |